Leave us a message
We are ready to answer you as soon as possible!
I consent to the processing of personal data and agree to the user agreement and privacy policy.
We are ready to answer you as soon as possible!
I consent to the processing of personal data and agree to the user agreement and privacy policy.
Showing all 4 results
ArthroVisc®40 is a non-cross-linked hyaluronic acid (2 %) obtained from bacterial fermentation.
This product is sterile and non-pyrogenic.
It is packaged in 2 ml syringes of hyaluronic acid ( 20 mg/ml, 1500 KDa).
ArthroVisc®40 is available in three syringes of 2 ml. It is for single use and designed to be used with sterile needles (25G or 27G), not supplied in the kit.
Composition :
2 mL of solution contains 40mg of hyaluronic acid in phosphate buffer (Sodium chloride, Dipotassium hydrogenphosphate, Potassium dihydrogenphosphate, Potassium chloride) and water for injection.
Thanks to its powerful action that stimulates collagen formation, it helps reduce wrinkles and expression lines, promoting skin hydration and cell regeneration from the inside.
Its liquid presentation means that collagen is absorbed more easily and quickly by the body and distributed to the deepest layers of the skin. Collagen production decreases from the age of 25. After the age of 40, it is reduced to 1%, which implies associated cellular aging, since the capacity to regenerate that collagen is lower.
BENEFITS:
Cellular Matrix® tubes allow the preparation of autologous platelet-rich plasma (RegenPRP®) combined with non-cross-linked hyaluronic acid (HA) in a closed-loop system.
CM-PRP-HA has an excellent safety profile in clinical practice.
Cellular Matrix® technology combines the complementary clinical effects of RegenPRP® and hyaluronic acid (HA), providing better, longer-lasting results in patients with osteoarthritis.
Hyaluronic acid
Cellular Matrix® tubes allow the preparation of autologous platelet-rich plasma (RegenPRP®) combined with non-cross-linked hyaluronic acid (HA) in a closed-loop system.
CM-PRP-HA has an excellent safety profile in clinical practice.
Cellular Matrix® technology combines the complementary clinical effects of RegenPRP® and hyaluronic acid (HA), providing better, longer-lasting results in patients with osteoarthritis.
Hyaluronic acid